Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 37-42

  Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antineutrophil cytoplasmic antibody; Treatment; Vasculitis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BLYS; MYCOPHENOLIC ACID; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; BLADDER INJURY; CHEMICAL CYSTITIS; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; METHOTREXATE; TREATMENT OUTCOME;

EID: 73649124627     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328331cfeb     Document Type: Review

References (53)

1. Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997; 349:553-558.
2. Flossmann O, Berden A, de groot K, et al. Longterm survival of ANCAassociated vasculitis. APMIS 2009; 117 (Suppl 127):139.
3. Watts R, Gonzalez-Gay M, Lane S, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60:170-172.
4. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66:605-617; Epub 2006 Dec 14.
5. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67:1004-1010; Epub 2007 Oct 2.
6. Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007; 46:1615-1616; Epub 2007 Sep 5.
7. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44. (Pubitemid 36765101)
8. Adu D, Pall A, Luqmani R, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997; 90:401-409.
9. Guillevin L, Cordier J, Lohte F, et al. A prospective, multicentre randomised trial comparing steroids and pulse cyclophosphomide versus steroids and oral cyclophosphomide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187-2198.
10. Rihova Z, Jancova E, Merta M, et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis - preliminary single center experience. Prague Med Rep 2004; 105:64-68.
11. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018-2027.
12. de Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670-680.
13. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93-100.
14. Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20:2725-2732; Epub 2005 Sep 27.
15. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798-802; Epub 2006 Dec 19.
16. Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23:1307-1312; Epub 2007 Dec 8.
17. Walsh M, Jayne D. Rituximab in the treatment of antineutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 2007; 72:676-682; Epub 2007 Jul 4.
18. Ferraro AJ, Drayson MT, Savage CO, Maclennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur J Immunol 2008; 38:292-298.
19. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-2168.
20. Ferraro AJ, Smith SW, Neil D, Savage CO. Relapsed Wegener's granulomatosis after rituximab therapy: B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant 2008; 23:3030-3032.
21. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540-1547.
22. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858; Epub 2005 Nov 3.
23. Jones RB, Walsh M, Jayne D, for the European Vasculitis Study Group. Randomised trial of rituximab versus cyclophosphamide for ANCA-associated vasculitis. J Am Soc Nephrol 2008; 19:61A.
24. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188; Epub 2007 Jun 20.
25. Little MA, Bhangal G, Smyth CL, et al. Therapeutic effect of anti-TNF-{alpha} antibodies in an experimental model of anti-neutrophil cytoplasm antibodyassociated systemic vasculitis. J Am Soc Nephrol 2006; 17:160-169; Epub 2005 Nov 23.
26. Huugen D, Xiao H, van Esch A, et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167:47-58.
27. Stone J, Uhlfelder M, Hellmann D, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis. Arthritis Rheum 2001; 44:1149-1154.
28. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109:1718-1723; Epub 2004 Mar 22.
29. WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
30. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 2007; 18:2189-2197.
31. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
32. de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469.
33. Jayne D, Chapel H, Adu D. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93:433-439.
34. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58:308-317.
35. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35:1150-1153.
36. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
37. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29:173-184. (Pubitemid 43041668)
38. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2009.
39. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century: a disease of older patients. Rheumatology (Oxford) 2005; 44:495-501.
40. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477-484.
41. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Annals Rheum Dis 2009; 68:310-317.
42. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009; 68:658-663.
43. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43:1841-1848.
44. Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60:1187-1192.
45. Morgan M, Turnbull J, Selemet U, et al. Increased incidence of cardiovascular events in patients with ANCA-associated vasculitis: matched pair cohort study. Arthritis Rheum (in press).
46. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621-631.
47. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58:2908-2918.
48. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20:1083-1092; Epub 2005 Apr 12.
49. Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009; 68:1125-1130. doi:10.1136/ard.2008.092429.
50. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440-1448.
51. Walsh M, Chaudhry A, Jayne DR. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67:1322-1327.
52. Mckinney E, Lyons P, Carr E, et al. A CD8 T cell memory transcription signature predicts prognosis in autoimmune disease. APMIS 2009; 17 (Suppl 127):127-129.
53. Tam FW, Sanders JS, George A, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004; 19:2761-2768; Epub 2004 Sep 7.